[Asia Economy Reporter Heo Kyung-jun] Kolon Life Science, a KOSDAQ-listed company, announced on the 25th that it will additionally acquire 300,000 shares of its biopharmaceutical manufacturing subsidiary Kolon Biotech for approximately 5.6 billion KRW.
After the stock acquisition, Kolon Life Science's stake in Kolon Biotech will reach 100%. The scheduled date for the stock acquisition is the 26th.
Kolon Life Science stated that the purpose of this stock acquisition is "to secure liquidity for the subsidiary."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
